About one in 10 U.S. adults reported past-year GLP-1 use, July-August 2025 CDC survey finds
A CDC Rapid Surveys System estimate found that about one in 10 U.S. adults reported using a GLP-1 medication in the past year. Many users reported compounded products or changes from prescribed use, pointing to cost and access pressures. The scale makes GLP-1 use a public health and health-system issue, not only a clinical prescribing question.
About one in 10 U.S. adults reported taking a glucagon-like peptide-1 receptor agonist, or GLP-1, medication during the past year, according to CDC data collected in July and August 2025 and published in Morbidity and Mortality Weekly Report. The finding describes self-reported use among adults, not a prescription database count. It places the medication class among widely used treatments for weight and metabolic conditions in the United States.
The CDC Rapid Surveys System asked adults whether they had used a GLP-1 medication in the previous 12 months. Among those reporting use, about one in five said they used a compounded version, which the Food and Drug Administration has not reviewed before marketing for safety, effectiveness or quality. About two in five reported changing how they used the medication from how it was prescribed, citing cost and availability.
The pattern shows demand extending beyond a narrow clinical group and into mainstream consumer health behavior. Compounding and dose or frequency changes can indicate that price, shortages, and access are shaping real-world use. Because GLP-1 drugs are used for obesity, diabetes and related conditions, broad uptake can affect insurance spending, pharmacy supply, and how clinicians manage long-term metabolic care. The report does not measure health outcomes, so it cannot show whether this level of use improves or harms population health.
The estimate matters because one in 10 adults represents a large population exposure to drugs with prescription oversight, supply constraints and cost pressures. The survey cannot prove effectiveness or safety at this scale; it is a cross-sectional, self-reported snapshot that can be affected by recall and social desirability. The authors note that future research could evaluate implications of real-world dose and frequency adjustments for safety and effectiveness in practice.
The finding affects adults, prescribers, insurers and pharmacies because broad GLP-1 use can strain access, shape spending and raise questions about unreviewed compounded medications.
Sources (2)
- [1]Original source(https://medicalxpress.com/news/2026-11-adults-glp-medication-july-august.html)
- [2]MMWR article(https://doi.org/10.15585/mmwr.mm7544a1)